Clinical trials: Gastro-Intestinal Disorders
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Gastroparesis
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
Motilin is a peptide whose action is controlled by motilin receptors located in the gut. Action of Motilin at motilin receptors increases the gastric emptying rate (rate of emptying of food and fluid from the stomach).
- Trial name
- NCT00562848
- Testing
- GSK962040
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Gastroesophageal Reflux Disease
The Use of International GerdQ Questionnaire
There are three main directions for use GerdQ in practice. First of all, GerdQ can be used to diagnose GERD with an accuracy comparable to the accuracy of diagnosis of GERD by the specialist (gastroenterologist).
- Trial name
- GERDq (NCT01489735)
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis
The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by…
- Trial name
- NCT01008696
- Testing
- Rabeprazole, Lansoprazole
- Volunteers
- 217 people
- Sponsor
- Janssen Korea, Ltd., Korea
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Gastroesophageal Reflux Disease
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years.
- Trial name
- NCT00132496
- Testing
- rabeprazole sodium
- Where
- 25 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eisai Inc.
Stomach Ulcer
Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
To examine the efficacy of continued administration of rebamipide following bacteria eradication therapy in patients with H. pylori-positive active gastric ulcer in a placebo-controlled, double-blind study
- Trial name
- NCT00233389
- Testing
- Rebamipide
- Where
- Japan
- Volunteers
- 301 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastric/Gastroesophageal Junction Cancer, Breast Cancer
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
- Conditions
- Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07036185
- Testing
- KJ015 Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Autism, Autistic Disorder
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in…
- Conditions
- Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases
- Trial name
- NCT00110708
- Testing
- Oralgam (human immunoglobulin)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- PediaMed Pharmaceuticals
Gastroesophageal Reflux
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease…
- Trial name
- NCT02030925
- Testing
- IW-3718
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Non-erosive Reflux Disease
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)
Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive reflux disease(NERD)
- Trial name
- NCT01750437
- Testing
- YH1885L(Revaprazan), Esomeprazole 20mg
- Where
- 10 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Yuhan Corporation
Gastroesophageal Reflux Disease
Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire.
- Trial name
- GerdQ-Greece (NCT00914342)
- Where
- 54 sites in Greece
- Volunteers
- 889 people
- Sponsor
- AstraZeneca
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Gastric Cancer, Colon Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
- Trial name
- NCT06010862
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.